Revolution Medicines, Inc. announced in connection with the closing of the Mergers, on the Effective Date, as contemplated by the Merger Agreement, the company board of directors appointed Sandra J. Horning, M.D., as a member of the Board. Dr. Horning will serve as a Class II director, with an initial term expiring at Revolution Medicines' 2025 annual meeting of stockholders. Dr. Horning was appointed to the Board as the EQRx designee, as provided for by the Merger Agreement.

Revolution Medicines determined that Dr. Horning qualifies as an independent director" for purposes of the Nasdaq Stock Market LLC listing standards.